RecruitingNCT06401577

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics (DREAM-ON) - An Observational Cohort Study From the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)


Sponsor

Milton S. Hershey Medical Center

Enrollment

800 participants

Start Date

Oct 16, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is following people after an episode of acute pancreatitis (sudden inflammation of the pancreas) to see how many develop diabetes or pre-diabetes, and why. Researchers will use continuous glucose monitors (CGMs) and blood tests to track metabolic changes over time. **You may be eligible if...** - You have been diagnosed with acute pancreatitis within the past 90 days - You are able to participate in all study activities including follow-up visits, blood tests, and glucose monitoring **You may NOT be eligible if...** - You have confirmed chronic pancreatitis (long-term pancreatic scarring) - You have had major pancreatic surgery in the past - You have a pancreatic tumor - You have severe kidney disease (eGFR less than 30) or are on dialysis - You have active cancer (other than non-melanoma skin cancer) - You have advanced liver disease - You are pregnant at the time of enrollment - You are currently incarcerated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDexcom Continuous Glucose Monitor (CGM)

Dexcom Continuous Glucose Monitor which measures and records a participant's serum glucose level


Locations(13)

University of Southern California

Los Angeles, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

Stanford University

Stanford, California, United States

University of Florida

Gainesville, Florida, United States

AdventHealth

Orlando, Florida, United States

Northwestern University

Chicago, Illinois, United States

University of Illinois at Chicago

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

Johns Hopkins University

Baltimore, Maryland, United States

University of Minnesota

Minneapolis, Minnesota, United States

Ohio State University

Columbus, Ohio, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Benaroya Research Institute

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06401577


Related Trials